Evidence-Based Care in Atopic Dermatitis: IL-13 Inhibitors to Treat Moderate to Severe Disease
Update: 2025-06-25
Description
In this episode, Andrew F. Alexis, MD, MPH; Daniel C. Butler, MD; and Shawn G. Kwatra, MD, discuss IL-13 inhibition for treating patients with moderate to severe atopic dermatitis (AD), including:
- The available biologic therapies that specifically target IL-13
- Where these agents fall in the 2024 American Academy of Dermatology treatment algorithm
- How these agents compare to other AD therapies like topical corticosteroids and oral JAK inhibitors
- A detailed patient case to highlight take home points
Presenter
Andrew F. Alexis, MD, MPH
Professor of Clinical Dermatology
Weill Cornell Medical College
New York, New York
Daniel C. Butler, MD
Assistant Dean Student Affairs
University of Arizona College of Medicine – Tucson
Tucson, Arizona
Shawn G. Kwatra, MD
Dr. Joseph W. Burnett Endowed Professor and Chair
Department of Dermatology
University of Maryland School of Medicine
Baltimore, Maryland
Program page:
https://bit.ly/4kTP04D
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
